Evidence map›Paper›PMID 28993384›Full record

ArticleBMJ open2017

Can coenzyme Q10 supplementation effectively reduce human tumour necrosis factor-α and interleukin-6 levels in chronic diseases? Protocol for a systematic review and meta-analysis of randomised controlled trials.

Farnaz Farsi, Javad Heshmati, Leila Janani, Pardis Irandoost, Naeimeh Mesri Alamdari, Abbasali Keshtkar, Abolfazl Akbari, Mohammadreza Vafa

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Farnaz FarsiDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Javad HeshmatiSonghor Healthcare Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Leila JananiDepartment of Biostatistics, School of Public Health, Iran University of Medical Sciences and Health Services, Tehran, Iran.
Pardis IrandoostDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Naeimeh Mesri AlamdariDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Abbasali KeshtkarDepartment of Health Sciences Education Development, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abolfazl AkbariColorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohammadreza VafaDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRKermanshah University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInflammation, as a critical factor, can cause numerous chronic diseases by creating various proinflammatory cytokines. Coenzyme Q10 (CoQ10) can potentially exert an anti-inflammatory agent; in turn, this agent can reduce the systemic inflammatory response. The aims of this study are to conduct a comprehensive systematic review and a meta-analysis for the determination of the CoQ10 efficacy on the changes in serum interleukin-6 (IL-6) and the tumour necrosis factor-α (TNF-α) levels in unhealthy subjects. METHOD AND ANALYSIS: We will conduct an electronic search for articles published between January 1990 and January 2017 using a prespecified search strategy in MEDLINE, SCOPUS, EMBASE, CENTRAL and Web of Science.Our search will focus only on randomised controlled clinical trials in unhealthy subjects that employ either a parallel or a crossover design; this search will involve concurrent control groups. The primary outcomes of the literature are to determine the CoQ10 efficacy on the changes in the serum IL-6 and the TNF-α levels in unhealthy subjects. Secondary outcomes such as body mass index, serum adiponectin and high-sensitivity C-reactive protein levels, lipid profile and the heterogeneity assessment of the primary studies will be evaluated. The stages of screen articles, the extracts of relevant data and the assessment of study quality using the Cochrane risk of bias tool will be conducted independently by the two reviewers. Any disagreement will be resolved by discussion with a third person. If the number of eligible studies is sufficient, we will carry out a meta-analysis according to both outcomes. ETHICS AND DISSEMINATION: This study is the protocol for a systematic review and no ethics approval is needed. The findings from the full systematic review will be published in a peer-reviewed journal, and they will also be exhibited at national/international academic and clinical conferences. TRIAL REGISTRATION NUMBER: CRD42016052200.

Indexed as

Dietary SupplementsBiomarkersChronic DiseaseHumansInterleukin-6Meta-Analysis as TopicRandomized Controlled Trials as TopicResearch DesignSystematic Reviews as TopicTumor Necrosis Factor-alphaUbiquinoneBiomarkerscoenzyme Q10Interleukin-6Tumor Necrosis Factor-alphaUbiquinonecoenzyme Q10cytokinesinflammatory responseinterleukin-6tumour necrosis factor-α

Identifiers

PMID28993384
PMCPMC5640052
OpenAlexW2763177614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.